57,000 Shares in Penumbra, Inc. $PEN Purchased by Sculptor Capital LP

Sculptor Capital LP purchased a new position in shares of Penumbra, Inc. (NYSE:PEN) in the 2nd quarter, Holdings Channel reports. The institutional investor purchased 57,000 shares of the company’s stock, valued at approximately $17,998,000.

A number of other hedge funds have also recently added to or reduced their stakes in PEN. Hsbc Holdings PLC increased its position in Penumbra by 2.3% during the 4th quarter. Hsbc Holdings PLC now owns 1,527 shares of the company’s stock worth $475,000 after purchasing an additional 35 shares during the period. Farther Finance Advisors LLC boosted its stake in shares of Penumbra by 27.1% in the fourth quarter. Farther Finance Advisors LLC now owns 178 shares of the company’s stock valued at $55,000 after buying an additional 38 shares in the last quarter. Swiss Life Asset Management Ltd grew its holdings in Penumbra by 2.3% during the fourth quarter. Swiss Life Asset Management Ltd now owns 1,728 shares of the company’s stock worth $537,000 after acquiring an additional 39 shares during the period. Keybank National Association OH grew its holdings in Penumbra by 1.2% during the fourth quarter. Keybank National Association OH now owns 3,705 shares of the company’s stock worth $1,152,000 after acquiring an additional 43 shares during the period. Finally, UMB Bank n.a. raised its position in Penumbra by 11.3% in the fourth quarter. UMB Bank n.a. now owns 442 shares of the company’s stock worth $137,000 after acquiring an additional 45 shares in the last quarter. Institutional investors and hedge funds own 88.88% of the company’s stock.

Penumbra Price Performance

PEN stock opened at $324.61 on Wednesday. Penumbra, Inc. has a 1 year low of $221.26 and a 1 year high of $362.41. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.86 and a current ratio of 5.75. The stock’s 50 day moving average price is $320.38 and its 200 day moving average price is $327.16. The firm has a market cap of $12.79 billion, a P/E ratio of 79.76, a PEG ratio of 2.01 and a beta of 0.70.

Penumbra (NYSE:PEN) last announced its earnings results on Thursday, July 30th. The company reported $0.88 EPS for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.28). The company had revenue of $390.05 million for the quarter, compared to analyst estimates of $389.64 million. Penumbra had a net margin of 10.67% and a return on equity of 10.50%. Penumbra’s quarterly revenue was up 14.9% compared to the same quarter last year. During the same quarter last year, the company posted $0.86 EPS. On average, sell-side analysts expect that Penumbra, Inc. will post 5.02 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have commented on PEN. Royal Bank Of Canada reissued a “sector perform” rating and issued a $374.00 target price on shares of Penumbra in a report on Thursday, June 11th. Evercore reiterated an “outperform” rating and issued a $320.00 price target on shares of Penumbra in a report on Monday, July 6th. Wall Street Zen upgraded shares of Penumbra to a “hold” rating in a research note on Saturday, May 9th. Zacks Research downgraded shares of Penumbra from a “hold” rating to a “strong sell” rating in a report on Monday, June 29th. Finally, Citigroup lowered their target price on shares of Penumbra from $374.00 to $350.00 and set a “neutral” rating on the stock in a research report on Thursday, May 7th. Three equities research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $367.07.

About Penumbra

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.